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Abstract
Purpose It has been shown that some primary human
tumours and their metastases, including prostate and breast
tumours, overexpress gastrin-releasing peptide (GRP) recep-
tors. Bombesin (BN) is a neuropeptide with a high affinity
for these GRP receptors. We demonstrated successful
scintigraphic visualisation of BN receptor-positive tumours
in preclinical studies using the radiolabelled BN analogue
[111In-DTPA-Pro1,Tyr4]BN. However, the receptor affinity
as well as the serum stability of this analogue leave room
for improvement. Therefore new 111In-labelled BN ana-
logues were synthesised and evaluated in vitro and in vivo.
Methods and results The receptor affinity of the new BN
analogues was tested on human GRP receptor-expressing
prostate tumour xenografts and rat colon sections. Analogues
with high receptor affinity (low nM range) were selected for
further evaluation. Incubation in vitro of GRP receptor-
expressing rat CA20948 and human PC3 tumour cells with
the 111In-labelled analogues resulted in rapid receptor-
mediated uptake and internalisation. The BN analogue with
the best receptor affinity and in vitro internalisation character-
istics, Cmp 3 ([111In-DTPA-ACMpip5,Tha6,βAla11,Tha13,
Nle14]BN(5–14)), was tested in vivo in biodistribution studies
using rats bearing GRP receptor-expressing CA20948
tumours, and nude mice bearing human PC3 xenografts.
Injection of 111In-labelled Cmp 3 in these animals showed
high, receptor-mediated uptake in receptor-positive organs
and tumours which could be visualised using planar gamma
camera and microSPECT/CT imaging.
Conclusion With their enhanced receptor affinity and their
rapid receptor-mediated internalisation in vitro and in vivo,
the new BN analogues, and especially Cmp 3, are
promising candidates for use in diagnostic molecular
imaging and targeted radionuclide therapy of GRP recep-
tor-expressing cancers.
Keywords Biodistribution . Prostate cancer .
Molecular imaging . Gastrin-releasing peptide receptor .
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Introduction
Bombesin-like peptides, including gastrin-releasing peptide
(GRP) and neuromedin B (NMB), are involved in the
regulation of a large number of biological processes in the
gut and central nervous system (CNS) [1]. They mediate
their action by binding to G protein-coupled receptors [2].
Four subtypes of the bombesin (BN) receptor are known.
Three of them, the NMB receptor (BB1), the GRP receptor
(BB2) and BN receptor subtype 3 (BRS-3 or BB3), are
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mammalian receptors, whereas the fourth subtype (BB4) is
found only in amphibians [3–6]. Except for the GRP
receptor, these receptor subtypes are not characterised very
well with regard to their distribution and function in human
tissues [7, 8].
BN receptors are expressed in high densities on several
primary human tumours and their metastases, including
prostate, breast, small cell lung and pancreatic cancers [9–
16]. Prostate cancer is the most frequently diagnosed
malignancy and the third leading cause of cancer mortality
among men in the Western world [17]. Although the
commonly used hormonal therapies increase the survival
of patients with hormone-dependent prostate tumours,
patients with hormone-independent tumours still have a
poor prognosis. Therefore new diagnosis and treatment
methods for these tumours are still very welcome.
Prostate tumours overexpress GRP receptors [11, 14,
18–21]. In an autoradiographic study, Markwalder and
Reubi found the GRP receptor to be expressed in high
density on invasive prostate carcinomas and proliferative
intraepithelial prostate lesions, mostly prostatic intraepithe-
lial neoplasias, whereas normal prostate tissue and, in most
cases, hyperplastic prostate tissue were GRP receptor-
negative [14]. These findings suggest that the GRP receptor
can be used as a molecular basis for diagnosing and treating
prostate tumours with, for example, GRP receptor-targeted
scintigraphy, radionuclide therapy and cytotoxic therapy
[14, 22]. It has been proposed that GRP receptor-expressing
tumours can be visualised and treated using radiolabelled
BN analogues in a manner similar to what has been found
for somatostatin receptor-expressing tumours, which have
been successfully imaged and treated using radiolabelled
somatostatin analogues [23–25].
A number of researchers continue to work on the
development of radiolabelled BN analogues that specifically
target GRP receptor-expressing tumours. For example, 99mTc-
and 111In-coupled BN analogues have been developed for
diagnostic SPECT imaging and 64Cu- and 68Ga-labelled
analogues for PET imaging of GRP receptor-expressing
tumours [26–39]. In addition, 90Y- and 177Lu-labelled
analogues have been described as promising tools for
targeted radiotherapy of these tumours [26, 40].
We previously developed and evaluated the radiolabelled
peptide [111In-DTPA-Pro1,Tyr4]BN, a BN analogue which
internalised rapidly into GRP receptor-positive tumour cells
in vitro and in vivo [37–39]. In addition, GRP receptor-
expressing CA20948 and AR42J tumours could be visual-
ised using gamma camera imaging in rats after injection
with this radiolabelled BN analogue [37, 38].
Our goal in this study was to extend our previous study by
developing an improved BN analogue with an increased
uptake in GRP receptor-expressing tumours. Because the BN
analogue, Cmp 1 [DTPA-Pro1,Tyr4]BN is an analogue with
minimal modifications of the native peptide, we synthesised
new BN analogues with shortened amino acid sequences
including stable amino acid derivatives to increase the
receptor affinity of these peptides. We selected five of these
new BN analogues on the basis of their receptor affinity and
compared their in vitro characteristics with the characteristics
of Cmp 1. We determined the in vivo tumour uptake and
tissue biodistribution of the compound found to have the
most promising in vitro characteristics.
Materials and methods
Peptide synthesis
The new BN analogues were synthesised by solid phase
peptide synthesis using an Applied Biosystems Model
432A “Synergy” Peptide synthesiser (Applied Biosystems,
Foster City, CA, USA) employing the Fmoc (9-fluorenyl-
methoxy-carbonyl) strategy. The instrument protocol re-
quired 25 μmol of starting resin and 75 μmol of subsequent
Fmoc-protected amino acids activated by a combination of
N-hydroxybenzotriazole (HOBt) and (2-(1-H-benzotriazol-
1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU). Tri-t-butyl DTPA (75 μmol) was placed at the
appropriate location in an amino acid column to prepare
DTPA-coupled derivatives [19]. The arginine and lysine
derivatives used were purchased from RSP Amino Acid
Analogues (Hopkinton, MA, USA). All other Fmoc-
protected amino acids were purchased from Novobio-
chem/EMD Biosciences (Madison, WI).
The cleavage and deprotection were accomplished using
85% TFA:5% thioanisole:5% phenol:5% water. We isolated
the crude peptide by precipitating with t-butyl methyl ether
(Sigma, St. Louis, MO, USA), and purified the peptide by
reverse phase high-performance liquid chromatography
(HPLC) using an acetonitrile/water gradient containing
0.1% TFA, with final yields ranging from 10% to 25% of
the starting resin scale. The molecular weights of com-
pounds 1 through 6 were determined by mass spectrometry
operating in the electrospray mode (Varian, Palo Alto, CA,
USA); M/z determined for the peptides were: Cmp 1,
1,016.0 (M+2H), consistent for a compound of expected
MW of 2,030.0; Cmp 2, 1,515.6 (M+H); Cmp 3, 1,644.7
(M+H); Cmp 4, 1,638.8 (M+H), Cmp 5, 1,504.8 (M+H);
Cmp 6, 1,431.8 (M+H).
Peptide radiolabelling
The DTPA-conjugated BN analogues were radiolabelled with
111In (111InCl3, Tyco Healthcare, Petten, the Netherlands,
DRN 4901, 370 MBq/ml in HCl, pH 1.5–1.9) to a maximum
specific activity of 200 MBq/nmol as described previously
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[41]. Consecutive quality control by instant thin-layer
chromatography and SEP-PAK C18 reverse phase chroma-
tography (Waters) was performed as described previously
[42]. The radiolabelling yield and radiochemical purity were
always >95%.
Receptor affinity
Receptor affinity of the BN analogues was determined on
frozen sections of the GRP receptor-expressing human
prostate tumour xenograft PC-295 [43] and rat colon using
in vitro autoradiography. The 10-μm sections were incu-
bated for 1 h at room temperature with 0.1 nM111In-Cmp 1
(111In-DTPA-Pro1,Tyr4-bombesin) (200 MBq/nmol) in
167 mM Tris (pH 7.6), 5 mM MgCl2, 1% bovine serum
albumin (BSA), 40 μg/ml bacitracin. To generate compet-
itive inhibition curves, the sections were incubated in the
presence of increasing amounts of the selected non-
radioactive 115In-labelled BN analogues. After incubation,
the sections were washed two times for 5 min each in
167 mM Tris (pH 7.6), 5 mM MgCl2, 0.25% BSA (4°C),
for 5 min in 167 mM Tris (pH 7.6), 5 mM MgCl2 (4°C) and
finally rinsed in MilliQ water (4°C). The sections were then
dried and exposed to phosphor imaging screens for 72 h.
The imaging screens were read using the Cyclone Storage
Phosphor System and the autoradiograms were quantified
using Optiquant Software (Packard, Meriden, USA).
Cell culture
The BN analogues were tested using the GRP receptor-
expressing rat pancreatic tumour cell lines CA20948 and
AR42J [44] and the human prostate tumour cell line PC3.
We have previously used the CA20948 tumour model to
characterise BN analogues. Many other groups, however,
have used the AR42J tumour model. In this study we used
both models to enable comparisons with other studies.
The CA20948 cells were grown in Dulbecco’s modified
Eagle’s medium (Gibco, Life Technologies, Breda, the Nether-
lands) supplemented with 10% foetal bovine serum, Glutamax
I (1x), 0.2 mM sodium pyruvate, 0.25 mg/l Fungizone and
200 IU/ml penicillin/streptomycin (Gibco, Life Technologies,
Breda, the Netherlands). The AR42J and PC3 cells were
grown in RPMI medium (Gibco, Life Technologies, Breda,
the Netherlands) supplemented with 10% foetal bovine
serum, Glutamax I (1x), 0.2 mM sodium pyruvate,
0.25 mg/l Fungizone and 200 IU/ml penicillin/streptomycin
(Gibco, Life Technologies, Breda, the Netherlands).
Internalisation
The internalisation characteristics of the 111In-labelled BN
analogues were determined as previously described [45].
Subconfluent cell cultures were transferred to six-well
plates 24 h before internalisation experiments. For increas-
ing incubation times, the CA20948 and PC3 cells were
incubated in triplicate with 1 ml incubation medium (RPMI
supplemented with 20 mM HEPES and 1% bovine serum
albumin) containing 80–100 kBq of 111In-labelled peptide
(concentration as indicated).
Cellular uptake was stopped by removing medium from
the cells and washing with 2 ml of ice-cold PBS. Surface-
bound activity was removed by incubation with 1 ml of
20 mM sodium acetate in PBS (pH 5.0) for 10 min.
Internalised and surface-bound radioactivity was deter-
mined separately by measuring the different fractions in an
LKB-1282-Compugamma system (Perkin Elmer, Oosterh-
out, the Netherlands) and expressed as a percentage of the
total dose applied per milligram cellular protein. Protein
was determined using a commercially available kit
(Protein assay, BioRad, Veenendaal, the Netherlands). To
test the receptor specificity of internalisation, an increas-
ing concentration (10−10 M to 10−6 M) of unlabelled [Tyr4]
BN was added to the incubation medium to compete with
the binding of radiolabelled BN analogues to the GRP
receptor.
Biodistribution experiments
The biodistribution experiments were done using male
Lewis rats implanted with an average of 1 million CA20948
cells and male NMRI nu/nu mice implanted with an
average of 5 million PC3 cells. After 14–21 days (tumour
size ca. 2–4 cm2 for CA20948 and 1 cm2 for PC3) the
animals were injected intravenously with 2–4 MBq/0.1 μg
of 111In-labelled peptide. In this biodistribution study we
compared the uptake of the most promising compound
(based on the binding affinity and internalisation results),
111In-Cmp 3, with the uptake of compound 111In-Cmp 1 in
the selected organs and tumours. The injection volume
was 0.50 ml in rats and 0.20 ml in mice. To discriminate
between receptor-specific (receptor-mediated) and non-
specific binding, some animals were co-injected with an
excess of unlabelled [Tyr4]BN (100 μg in rats and 50 μg
in mice). We sacrificed the animals 4, 24, 48 and 72 h
(mice only 4 h) after injection and collected the organs and
tissues of interest for counting radioactivity and calculat-
ing the uptake (% injected dose per mg tissue). Statistical
analysis was performed using the Mann Whitney and
unpaired t test. A probability of less than 0.05 was
considered significant.
Serum stability
The serum stability of 111In-Cmp 1 and 3 was evaluated by
incubation in human serum [50% serum:50% phosphate-
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buffered saline (PBS)] of healthy donors at 37°C for 4 h.
The percentage of intact peptide after incubation was
determined by separating degradation products by reverse
phase HPLC using a Vydac C-18 column connected to a
radiometric detector, and using a 15 min, 0–70% linear
acetonitrile gradient (0.1% TFA/water).
Tumour visualisation
The tumour visualisation experiments were done using a
male Lewis rat implanted with an average of 1 million
CA20948 cells in the right flank and AR42J cells in the left
flank. After 14–21 days, the rat was intravenously injected
with 4 MBq/0.1 μg 111In-Cmp 3. Directly after injection of
the radiotracer, a dynamic planar scan of the rat was made
over 1 h using a one-headed gamma camera (Siemens,
Erlangen, Germany). At 4 h after injection, a static image
was acquired for 1 min. Immediately after imaging at 4 h
post injection, the rat was sacrificed and a biodistribution
study was performed.
For microSPECT/CT imaging a female Swiss nu/nu
mouse was injected with ca. 1 million CA20948 cells. After
14 days the mouse was intravenously injected with
10 MBq/0.1 μg 111In-Cmp 3. Four hours after injection,
SPECT/CT imaging was performed with a four-headed
multiplexing multi-pinhole NanoSPECT/CT (Bioscan Inc.,
Washington D.C.). After the acquisition, the data were
reconstructed iteratively with the HiSPECT software (Bio-
scan Inc., Washington D.C., USA), a dedicated ordered
subsets-expectation maximisation (OSEM) software pack-
age for multiplexing multi-pinhole reconstruction. The CT
and SPECT images were fused using Pmod image fusion
software (Mediso Ltd., Budapest, Hungary). Immediately
after imaging at 4 h post injection the mouse was sacrificed
and a biodistribution study was performed.
Results
Peptides
Figure 1 shows the sequences and the molecular weights of
compounds 1–6 used in this study and the structures of the
non-natural amino acid derivatives.
Receptor affinity
The receptor affinity of the BN analogues was determined
on GRP receptor-expressing human prostate tumour xeno-
grafts (PC-295) and rat colon sections. The IC50 values of
the BN analogues are presented in Table 1. Cmp 2, Cmp 3
and Cmp 4 show increased receptor affinity for both the
human (0.50, 0.36 and 0.41 nM respectively) and rat (0.22,
0.08 and 0.31 nM respectively) GRP receptor compared
with analogue Cmp 1 (human 1.40 nM and rat 2.28 nM).
However, all analogues show improved receptor affinity for
the rat GRP receptor.
Internalisation
All the 111In-labelled BN analogues internalised into














































Compound 1 DTPA-Pro-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2 2030
Compound 2 DTPA-Acp-Gln-Trp-Ala-Val- Ala-His-Phe-Nle-NH2 1514
Compound 3 DTPA-ACMpip-Tha-Gln-Trp-Ala-Val- Ala-His-Tha-Nle-NH2 1644
Compound 4 DTPA-ACMpip-Tha-Gln-Trp-Ala-Val- Ala-His-Phe-Nle-NH2 1638
Compound 5 DTPA-DTha-Gln-Trp-Ala-Val- Ala-His-Tha-Nle-NH2 1504
Compound 6 DDpr(DTPA)-Gln-Trp-Ala-Val- Ala-His-Phe-Nle-NH2 1431
Fig. 1 Sequences of [DTPA-
Pro1,Tyr4]BN (compound 1)
and five new BN analogues,
including non-natural
amino acid derivatives
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of internalisation into the CA20948 (a) and PC3 (b) cells
expressed as percent of the dose per milligram cellular
protein of the different radiolabelled peptides. All the 111In-
labelled BN analogues internalised time dependently, but,
compared with 111In-Cmp 1, the new BN analogues were
more rapidly internalised into the CA20948 tumour cells.
The internalisation characteristics of the analogues in the
human PC3 cells were in some cases significantly different
from those found in the rat CA20948 cells. In addition, the
rank orders of the analogues based on these internalisation
data area under the curve (AUC)] are notably different in
the rat and human tumour cells (Fig. 2).
111In-Cmp 3 showed the highest rate of internalisation in
the first hours of incubation and had the highest AUC in
both the rat and the human tumour model. On the basis of
these internalisation data and the data on receptor affinity
for the human and the rat GRP receptor, we selected
analogue 111In-Cmp 3 for further in vitro and in vivo
characterisation.
To prove that the internalisation of 111In-Cmp 3 is
receptor specific, we added increasing amounts of unla-
belled [Tyr4]BN to the incubation medium, which
contained 10−10 M111In-Cmp 1 or 111In-Cmp 3. The results
in Fig. 3 show that addition of 1–10 nM unlabelled [Tyr4]
BN effectively caused this peptide to compete with the
uptake of either 111In-Cmp 1 or 111In-Cmp 3 for receptor
binding and internalisation into CA20948 cells and PC3
cells. Consistent with the findings in the time curve
internalisation study (Fig. 2), the superior internalisation
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111In-Cmp 1: 2370  (6)
111In-Cmp 2: 3105  (5)
111In-Cmp 3: 4080  (1)
111In-Cmp 4: 3207  (4)
111In-Cmp 5: 3451  (3)
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111In-Cmp 5: 328    (6)















Fig. 2 Time curve of internal-
isation of 0.5 nM111In-Cmp 1
and four new 111In-labelled BN
analogues in rat CA20948 tu-
mour cells (a) and human PC3
tumour cells (b). Results are
presented as the average per-
centage of the total dose per
milligram cellular protein (%
dose/mg protein; mean±SD).
AUC: area under the curve
Table 1 GRP receptor-binding affinity (IC50, mean±SD) of BN
analogues, determined on human PC-295 and rat colon sections
Analogue GRP receptor affinity
Rat colon IC50 (nM) Human PC-295 IC50 (nM)
Compound 1 2.28±0.57 1.40±0.07
Compound 2 0.22±0.05 0.50±0.05
Compound 3 0.08±0.01 0.36±0.01
Compound 4 0.31±0.02 0.41±0.01
Compound 5 0.43±0.04 2.54±0.34
Compound 6 1.20±0.01 15.39±2.81
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characteristics of 111In-Cmp 3 over 111In-Cmp 1 are less
impressive in the human PC3 cells than in the rat CA20948
cells.
Biodistribution
In the in vivo biodistribution studies we compared the
uptake of 111In-Cmp 3 with that of 111In-Cmp 1 in rats
bearing CA20948 tumours and nude mice bearing PC3
tumours. Compared with 111In-Cmp 1, the uptake of 111In-
Cmp 3 was two to three times higher (4 h post injection) in
the rat BN receptor-positive pancreas, stomach, caecum,
small intestine and colon (p<0.007) (Table 2). The same
was true for the uptake in the receptor- positive CA20948
tumour (p<0.015). The radioactivity in the background
organs and blood, except for the kidneys, was also two to
three times higher for 111In-Cmp 3 than for 111In-Cmp 1,
but was still very low, indicating rapid clearance. Co-
injection of 100 μg unlabelled [Tyr4]BN resulted in an 89%
reduction in 111In-Cmp 3 uptake in the CA20948 tumour
and also in a reduction in uptake in other GRP receptor-
positive organs, e.g. 94% in the pancreas and 88% in the
colon. The uptake reduction found for 111In-Cmp 1 was
comparable to that for 111In-Cmp 3: 90% in the tumour,
99% in the pancreas and 88% in the colon. As presented in
Table 2, 111In-Cmp 3 showed good retention in receptor-
positive organs and tumour up to 72 h post injection. Due
to rapid clearance from the body, good tumour-to-back-
ground ratios were found (Table 2). The respective tumour-
to-blood and tumour-to-muscle ratios were 50 and 126 for
111In-Cmp at 1 and 4 h post injection, and 49 and 146 for
111In-Cmp 3 at 4 h post injection; for 111In-Cmp 3 these
ratios respectively reached 133 and 89 at 72 h post
injection.
The results found in the PC3 tumour-bearing nude mice
at 4 h post injection were partly consistent with the results
found in the CA20948 tumour-bearing rats; 111In-Cmp 3
showed a two times higher uptake in the BN receptor-
positive organs compared with 111In-Cmp 1 (p<0.005 for
pancreas, caecum, small intestine and colon). The uptake of
111In-Cmp 3 in the human PC3 tumour was 1.3-fold higher
compared with 111In-Cmp 1 (Table 3). However, the
radioactivity accumulation in the mouse kidneys was four
times lower for the new compound 111In-Cmp 3
(p<0.0001). The uptake reduction in the blocking experi-
ments in the mice was consistent with the uptake reductions
found in the rats: 86% in PC3 tumour for both compounds,
96% for Cmp 3 in mouse pancreas (Cmp 1: 99%) and 95%
for Cmp 3 in mouse colon (Cmp 1: 96%). Respective
tumour-to-blood and tumour-to-muscle ratios in these PC3
tumour-bearing mice were 28 and 36 for 111In-Cmp 1 and
18 and 49 for 111In-Cmp 3 at 4 h post injection.
Serum stability
The in vitro serum stability of the 111In-Cmp 3 was
determined and compared with the stability of 111In-Cmp
1. The percentage of intact peptide after the 4-hour
incubation of 111In-Cmp 1 in human serum was 67%.
Under the same conditions 111In-Cmp 3 showed a slightly
increased stability of 74% intact peptide.
Tumour visualisation
To visualise GRP receptor-expressing tumours in rats using
the newly developed BN analogue, we injected a Lewis rat
bearing GRP receptor-expressing tumours [CA20948 (right
flank) and AR42J, which is commonly used by many other
research groups (left flank)] with 4 MBq/0.1 μg 111In-Cmp
3. Gamma camera imaging was performed directly after
injection and at 4 h after injection. Figure 4 shows scan
images at 1, 10, 30 and 60 min and at 4 h after injection.
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Fig. 3 Internalisation of 0.1 nM111In-Cmp 1 and 111In-Cmp 3 in the
rat CA20948 (a) and human PC3 (b) tumour cells after 1-h incubation
with increasing amounts of unlabelled [Tyr4]BN. Results are the
average percentage of the total dose per milligram cellular protein (%
dose/mg protein); mean±SD of three experiments
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The scan images in Fig. 4 demonstrate rapid uptake of
111In-Cmp 3 in GRP receptor-positive AR42J tumour;
uptake in this tumour could already be detected at 1 min
post injection. At 4 h post injection, the AR42J tumour was
still clearly visible. In this experiment the uptake of 111In-
Cmp 3 in the CA20948 tumour was much lower than the
uptake in the AR42J tumour. This was probably due to
necrosis of the huge CA20948 tumour and higher GRP
receptor density of the AR42J tumour.
The background radioactivity rapidly decreased after the
first hour, which resulted in increasing tumour-to-back-
ground ratios. As 111In-Cmp 3 is excreted via the kidneys
Table 3 Uptake of 111In-Cmp 1 and 111In-Cmp 3 in nude mice bearing PC3 tumours at 4 h p.i. (0.1 μg /4 MBq with or without co-injection of
100 μg unlabelled [Tyr4]BN)
111In-Cmp 1 111In-Cmp 3
4 h (n=17) 4 h + unlabelled BN
(n=10)
4 h (n=11) 4 h + unlabelled BN
(n=7)
Blood 0.023±0.007 0.029±0.014 0.047±0.012 0.035±0.020
Spleen 0.371±0.207 0.069±0.029 0.482±0.251 0.060±0.026(6)
Pancreas 8.486±3.983 0.100±0.042 15.010±3.930 0.553±0.312
Kidney 4.750±1.248 3.849±1.215 1.072±0.293 0.727±0.283
Liver 0.082±0.025 0.117±0.040 0.223±0.085 0.226±0.124
Stomach 0.666±0.528 0.070±0.048(6) 0.550±0.233(5) 0.056±0.061(3)
Caecum 1.556±0.620 0.120±0.075(9) 3.306±0.530(9) 0.409±0.130(5)
Small intestine 0.769±0.296 0.116±0.054 1.560±0.512 0.152±0.179
Colon 2.457±1.119 0.090±0.076 3.986±1.227 0.187±0.114
Muscle 0.040±0.094 0.019±0.011 0.017±0.016(10) 0.009±0.006(6)
Femur 0.018±0.016(16) 0.033±0.015 0.083±0.028(8) 0.026±0.010(4)
PC3 0.651±0.243(6) 0.089±0.070(7) 0.838±0.577(8) 0.120±0.122(6)




Results are the average uptake values of three or four experiments presented as percent of the injected dose per gram tissue (%ID/g) ±SD.
(x) =n
Table 2 Uptake of 111In-Cmp 1 and 111In-Cmp 3 in rats bearing CA20948 tumours at 4, 24, 48 and 72 h p.i. (0.1 μg /4 MBq with or without co-
injection of 100 μg unlabelled [Tyr4]BN)
111In-Cmp 1 111In-Cmp 3
4 h (n=6) 4 h + unlabelled
BN (n=3)
4 h (n=27) 4 h + unlabelled
BN (n=20)
24 h (n=6) 48 h (n=3) 72 h (n=3)
Blood 0.005±0.001 0.005±0.002 0.012±0.006 0.012±0.006 0.007±0.002 0.003±0.000 0.002±0.000
Spleen 0.023±0.018 0.020±0.003 0.029±0.014 0.033±0.008 0.034±0.014 0.031±0.006 0.029±0.009
Pancreas 1.307±0.260 0.018±0.005 2.883±1.135 0.185±0.520 2.227±0.347 1.332±0.629 1.165±0.169
Kidney 1.085±0.195 1.546±0.309 1.145±0.352 1.188±0.553 1.203±0.250 0.834±0.086 0.698±0.046
Liver 0.024±0.007 0.023±0.004 0.040±0.013 0.041±0.014 0.035±0.006 0.027±0.007 0.028±0.005
Stomach 0.054±0.021 0.015±0.007 0.136±0.068 0.068±0.049 0.085±0.023 0.051±0.030 0.036±0.005
Caecum 0.248±0.035 0.138±0.010 0.692±0.162 0.179±0.134 0.487±0.104 0.186±0.082 0.140±0.010
Small intestine 0.103±0.047 0.050±0.007 0.375±0.207 0.219±0.364 0.192±0.056 0.122±0.065 0.060±0.022
Colon 0.229±0.013 0.028±0.023 0.550±0.195 0.068±0.058 0.337±0.101 0.137±0.057 0.088±0.016
Muscle 0.002±0.001 0.002±0.001 0.004±0.002 0.004±0.002 0.004±0.001 0.004±0.000 0.003±0.000
Femur 0.006±0.002 0.007±0.001 0.013±0.004(23) 0.009±0.004(17) 0.013±0.003 0.013±0.003 0.012±0.001
CA20948 0.251±0.277 0.026±0.005 0.583±0.244(25) 0.067±0.088 0.521±0.115 0.277±0.167 0.266±0.082
Tumour-to-normal tissue radioactivity ratios
Tumour/blood 50 49 74 92 133
Tumour/muscle 126 146 130 69 89
Tumour/kidney 0.2 0.5 0.4 0.3 0.4
Results are the average uptake values of one to five experiments presented as percent of the injected dose per gram tissue (%ID/g) ±SD.
(x) =n
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and the urinary system, radioactivity rapidly accumulated in
the kidneys in the first hour after injection. At 4 h post
injection, the radioactivity in the kidneys had decreased,
and therefore the tumour-to-kidney ratio was more favour-
able at this time point.
In addition to the dynamic gamma camera imaging we
also performed a microSPECT/CT imaging study with a
nude mouse bearing the CA20948 tumour. The mouse was
injected with 10 MBq/0.1 μg 111In-Cmp 3 and was scanned
at 4 h post injection. Immediately after imaging at 4 h post
injection, the mouse was sacrificed for determination of the
in vivo biodistribution of the compound. Figure 5 shows
the fused SPECT/CT images of the mouse. Biodistribution
results are presented in the adjacent table. The sagittal,
coronal and transaxial slices show a clear localisation of the
CA20948 tumour on the right shoulder of the mouse, with
no interfering background radioactivity. On the sagittal
slice, bowel activity is visible which is probably caused by
the GRP receptor-positive pancreas and intestines.
The tumour uptake in the CA20948 tumour-bearing
nude mouse was much higher than that found in the
CA20948 tumour-bearing rats, which resulted in very high
tumour-to-background ratios.
Discussion
The overexpression of peptide receptors in human tumours
is of considerable clinical interest [46]. It has been shown
that the overexpression of somatostatin receptors on
human neuroendocrine tumours can be targeted success-
fully. On the one hand, long-term octreotide treatment of
patients with somatostatin receptor-expressing tumours
has been successful in relieving the symptoms related to
excessive hormone production by these tumours [47]. On
the other hand, the use of radiolabelled somatostatin
analogues has permitted visualisation of in vivo neuroen-
docrine tumours and their metastases in patients [24]. In
addition, 177Lu- and 90Y-labelled somatostatin analogues
have been used in radionuclide therapy in this group of
patients [48–55].
It has been reported that the GRP receptor is expressed
in high densities on prostate cancers [11, 14, 18–22]. Based
on this fact, and the experience with somatostatin receptors,
we conclude that targeting the GRP receptor could be the
molecular basis for clinical applications such as diagnostic
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Fig. 4 Planar gamma camera images of a rat bearing a CA20948
tumour in the right flank and an AR42J tumour at the left flank 1, 10, 30
and 60 min and 4 h after injection of 0.1 μg 111In-Cmp 3 (4 MBq).
Biodistribution data obtained from this rat immediately after imaging
at 4 h post injection are shown in the adjacent table. The uptake values
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Fig. 5 MicroSPECT/CT images
of a Swiss nu/nu mouse
bearing a CA20948 tumour
on the right shoulder at 4 h
post injection of 0.1 μg
111In-Cmp 3 (10 MBq).
Biodistribution data obtained
from this mouse immediately
after imaging at 4 h post
injection are shown in the
adjacent table. The uptake
values are presented as
%ID/g tissue
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With its 27 amino acid sequence, the GRP peptide has poor
in vivo stability and has not been found to be useful as a
diagnostic or therapeutic agent. The carboxyl-terminal deca-
peptide of GRP is similar to that of the 14-amino acid peptide
BN [56]. BN has a high affinity for the GRP receptor, which
makes the development of optimised radiolabelled analogues
of the BN peptide a very interesting goal.
As we previously reported, BN analogue [DTPA-Pro1,
Tyr4]BN (Cmp 1) is capable of visualising GRP receptor-
positive tumours in vivo. In this study we developed new
DTPA-coupled BN analogues with shortened amino acid
sequences containing non-natural amino acid derivatives to
improve the receptor binding affinity of the compounds.
The results of the present study show that shortening the
amino acid sequence and replacing amino acids by
derivatives in the BN analogues improves the receptor
affinity for both the rat and the human GRP receptor
(Table 1). The new compounds internalised rapidly into
GRP-receptor expressing rat and human tumour cells in
vitro. In in vivo biodistribution studies, 111In-Cmp 3
showed a two to three times higher uptake in the GRP
receptor-positive pancreas, CA20948 tumour (1.3 times for
PC3) and also the whole gastro-intestinal tract compared
with 111In-Cmp 1, with a good retention up to 72 h post
injection. This good receptor-mediated tumour uptake and
retention of 111In-Cmp 3 combined with its rapid clearance
from the body (Table 2) resulted in good tumour-to-blood
and tumour-to-muscle ratios ranging from 49 and 146
respectively at 4 h post injection up to 133 and 89
respectively at 72 h post injection in the CA20948
tumour-bearing rats. In the CA20948 mouse model the
respective CA20948 tumour-to-blood and tumour-to-mus-
cle ratios even reached 99 and 234 (Fig. 5). These ratios
compare well with those reported for other radiolabelled
BN analogues in the literature [26–31, 36, 40]. For
example, the recently published 111In-BZH1 and 111In-
BZH2 showed tumour-to-muscle ratios in AR42J tumour-
bearing rats of 171 and 99 respectively, compared with 146
for 111In-Cmp 3 at 4 h post injection [26].
This study shows that shortening the amino acid
sequence and replacing specific amino acids in the BN
sequence can yield compounds with improved receptor
affinity (Table 1). In preliminary studies we found that
substitution of the native asparagine at position 6 with other
amino acid derivatives did not always adversely affect
receptor binding affinity, and the derivatives presented here
are examples of modifications which were found to be
beneficial. Additionally, not all shortened peptides have
improved stability. For example, a peptide identical to Cmp
3, except with the aCMpip at position 5 deleted, has only
32.9% intact peptide left after 4-h incubation in human
serum (data not shown), indicating that minor changes in the
BN amino acid sequence can have a marked effect on the
peptide’s stability. In the case of Cmp 3, the characteristic
responsible for the increased internalisation in vitro and in
vivo is the enhanced receptor affinity and not the serum
stability, for the stability of this compound was only
marginally improved compared with Cmp 1.
Gamma camera imaging of a CA20948 and AR42J
tumour-bearing rat injected with 111In-Cmp 3 showed that
the tumour could be visualised as early as at 1 min post
injection (Fig. 4). MicroSPECT imaging of a CA20948
tumour-bearing nude mouse injected with the same com-
pound resulted in clear tumour detection with very high
tumour-to-background ratios (Fig. 5).
The dose-limiting organs in peptide receptor radionu-
clide therapy using somatostatin analogues are the kidneys,
owing to the reabsorption and retention of these radio-
labelled peptides. In this case, the kidneys can be protected
by infusion of amino acids and by applying individual
dosimetry in order to keep the kidney radiation dose below
the maximum tolerated dose of 23–27 Gy [57]. However,
the effect of amino acid infusion on kidney retention of BN
analogues has not been published as yet. Nevertheless,
compared with somatostatin analogues these BN analogues
have an almost three times lower retention of radioactivity
in the kidneys, which is very favourable for their possible
use in radionuclide therapy.
It should be noticed that the in vitro and in vivo
characteristics of some of the analogues obtained in the
rat tumour models are sometimes the opposite of those
found in the human tumour model. These findings are in
agreement with the findings of Maina et al., who recently
reported that there are interspecies differences in structure
and pharmacology of human and animal GRP receptors
[58]. This could be a major pitfall when using rat receptor
models for selection of optimised analogues. Human
receptor models should therefore always be used to verify
the results obtained in rat receptor models. In this study,
Cmp 3 has superior receptor binding and internalisation
characteristics in both rat and human tumour models in
vitro as well as in vivo. In addition, Cmp 3 also showed
remarkable binding characteristics in primary human
prostate cancer sections (IC50=1.3 nM, data not shown).
We plan to study further improvement of the tumour
uptake of Cmp 3, e.g. by conjugating this BN analogue
with the DOTA chelator. Breeman et al. reported an
increased GRP receptor affinity and tumour uptake when
replacing the DTPA chelator with the DOTA chelator
coupled to the [Pro1,Tyr4]BN analogue (Cmp 1) [38].
Besides radiolabelling with 111In, this DOTA chelator
enables radiolabelling with positron emitters like 68Ga and
64Cu for diagnostic PET imaging and also with β-emitters
like 177Lu and 90Y; this may permit their use for
radiotherapy to treat GRP receptor-positive tumours [26,
27, 33, 34, 36, 40], comparable to the use of 90Y-labelled
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octreotide and 177Lu-labelled octreotate to treat somatostat-
in receptor-expressing tumours [48–55]. Also increasing the
receptor density on the tumours using gene therapy and,
even more interestingly, delivering the radiolabelled ana-
logue directly to the tumour using intratumoral injections to
improve tumour uptake are to be studied.
In conclusion, the five new BN analogues were
compared with analogue Cmp 1 concerning receptor
binding affinity and in vitro internalisation into GRP
receptor-expressing tumour cells. In addition, Cmp 3, with
the best prospects based on the results of these studies, was
further characterised in vivo for biodistribution and
retention characteristics in tumour-bearing rats and mice.
We found that 111In-Cmp 3 has good uptake in both rat
and human GRP receptor-expressing tumours, which
makes this analogue a good candidate for molecular
imaging and therapy of GRP receptor-positive prostate
tumours.
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